Their studies demonstrated that combinations of selective inhibitors targeting HER2 and EGFR were able to significantly inhibit the growth of cetuximab-resistant CRC cells, and induce long-lasting tumor regression in experimental models [104, 105]. Here, ERBB2 is linked to neoplasm.